Gene therapy for ear tumors: Long-Term safety under review

NCT ID NCT07503613

ENROLLING_BY_INVITATION Disease control Sponsor: Akouos, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study follows 100 people with vestibular schwannoma (a non-cancerous ear tumor) who previously received a gene therapy called AAVAnc80-antiVEGF. Researchers will monitor for late side effects and measure tumor size changes over time using MRI scans. The goal is to understand the long-term safety and whether the therapy keeps working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AAVAnc80-antiVEGF gene therapy
What this could lead to: If successful, this could show that a single gene therapy injection safely controls tumor growth and reduces the need for repeated treatments.
What could go wrong: This is an observational follow-up study, not a new treatment test. It may reveal long-term risks like new tumors or immune problems, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VESTIBULAR SCHWANNOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acoustic neuroma hearing loss disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VESTIBULAR SCHWANNOMA

Contacts and locations

Locations

University of Texas Southwestern

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.